Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia

  • Mohammed Al Ghamdi1,
  • Khalid M. Alghamdi1,
  • Yasmeen Ghandoora1,
  • Ameera Alzahrani1,
  • Fatmah Salah1,
  • Abdulmoatani Alsulami1,
  • Mayada F. Bawayan1,
  • Dhananjay Vaidya2,
  • Trish M. Perl3 and
  • Geeta Sood3Email author
BMC Infectious DiseasesBMC series – open, inclusive and trusted201616:174

https://doi.org/10.1186/s12879-016-1492-4

Received: 30 September 2015

Accepted: 31 March 2016

Published: 21 April 2016

Abstract

Background

Middle Eastern Respiratory Syndrome coronavirus (MERS-CoV) is a poorly understood disease with no known treatments. We describe the clinical features and treatment outcomes of patients with laboratory confirmed MERS-CoV at a regional referral center in the Kingdom of Saudi Arabia.

Methods

In 2014, a retrospective chart review was performed on patients with a laboratory confirmed diagnosis of MERS-CoV to determine clinical and treatment characteristics associated with death. Confounding was evaluated and a multivariate logistic regression was performed to assess the independent effect of treatments administered.

Results

Fifty-one patients had an overall mortality of 37 %. Most patients were male (78 %) with a mean age of 54 years. Almost a quarter of the patients were healthcare workers (23.5 %) and 41 % had a known exposure to another person with MERS-CoV. Survival was associated with male gender, working as a healthcare worker, history of hypertension, vomiting on admission, elevated respiratory rate, abnormal lung exam, elevated alanine transaminase (ALT), clearance of MERS-CoV on repeat PCR polymerase chain reaction (PCR) testing, and mycophenolate mofetil treatment. Survival was reduced in the presence of coronary artery disease, hypotension, hypoxemia, CXR (chest X-ray) abnormalities, leukocytosis, creatinine >1 · 5 mg/dL, thrombocytopenia, anemia, and renal failure. In a multivariate analysis of treatments administered, severity of illness was the greatest predictor of reduced survival.

Conclusions

Care for patients with MERS-CoV remains a challenge. In this retrospective cohort, interferon beta and mycophenolate mofetil treatment were predictors of increased survival in the univariate analysis. Severity of illness was the greatest predictor of reduced survival in the multivariate analysis. Larger randomized trials are needed to better evaluate the efficacy of these treatment regimens for MERS-CoV.

Keywords

Middle Eastern Respiratory Syndrome coronavirus MERS CoV Coronavirus Survival Treatment outcome

Background

Coronaviruses cause a spectrum of illness from asymptomatic disease to respiratory failure. Early reports of coronavirus infections suggested that most infections were mild until the 2003 SARS epidemic that was associated with significant morbidity and mortality [1]. In September 2012, a novel coronavirus was identified in a 60-year old man in Saudi Arabia [2]. A second case was identified in a Qatari patient hospitalized in the United Kingdom [3]. The two coronaviruses were genetically identical and similar to isolates obtained from bats [4]. In July 2013, the coronavirus study group named this new virus Middle East respiratory syndrome coronavirus (MERS–CoV) [5].

As of December 21, 2015, there have been 1625 cases worldwide with 586 deaths [6]. The epidemiology and clinical manifestations of this disease have described a spectrum of illness from asymptomatic infection to severe respiratory failure and death. The overall mortality rate remains at 37 % [715]. Importantly, there are no known effective treatments. In 2014 there was an increase in MERS-CoV cases reported from the Jeddah region of Saudi Arabia. To describe the changing epidemiology and outcomes, we report the clinical features and treatment outcomes of patients admitted to a regional referral hospital in Jeddah, Saudi Arabia.

Methods

Study setting and participants

King Fahd General Hospital is an 800-bed hospital in Jeddah, Kingdom of Saudi Arabia and is a regional coronavirus referral center. There are 36 ICU beds and one Infectious Disease physician that serves the hospital. Between January through December 2014, all patients admitted or transferred to King Fahd Hospital with a positive MERS coronavirus PCR from clinical nasal swabs or nasopharyngeal aspirates were included.

Molecular methods

All PCR testing was performed at the Ministry of Health Regional Lab in Jeddah. The MagNa Pure Compact/MagNa Pure 96 (Roche) automated system was used to extract RNA from samples. Primers and probes for upE and Orf 1a targets of MERS-CoV were used from TIB MOLBIOL (Germany) along with Master Mix from Roche for the Light Cycler 480 II (Roche) were used to amplify upE and Orf 1a gene targets. Samples that tested positive for both upE and Orf 1a gene targets with a cycle threshold time of less than 37 were considered confirmed cases. Positive and negative controls were used to monitor the amplification process & to check for any inhibition of amplification.

Case review and definitions

Medical charts for all patients were reviewed and data abstracted on standardized data collection forms by an infectious disease trained physician. Demographic, clinical and laboratory data were entered into a database. To understand the epidemiology, age was categorized as <30, 30–60 and >60. Hypotension was defined as blood pressure <90/60 mm Hg, tachypnea as a respiratory rate greater than 16, hypoxia as an oxygen saturation <90 %, thrombocytopenia as platelets <150,000/cubic millimeter, leukopenia was defined as a white blood cell count <5000 cells/cubic millimeter and leukocytosis as a white blood cell count >10,000 cells/cubic millimeter. Renal insufficiency was defined as a creatinine >1.5 mg/dL. Liver function abnormalities were defined as a lactate dehydrogenase (LDH) >300 U/liter, alanine transaminase (ALT) > 50 U/Liter and aspartate aminotransferase (AST) >40 U/Liter. Immunosuppression was defined as AIDS, history of organ transplant, neutropenia, known malignancy, taking immunosuppressive medication and congenital immunodeficiency. Pregnancy was considered an immunosuppressed state.

A modified Acute Physiologic and Chronic Health Evaluation (APACHE 2) score was calculated using age, temperature, mean arterial blood pressure, respiratory rate, potassium, creatinine, acute renal failure, and comorbid conditions to estimate severity of illness [16]. PaO2 was estimated using pulse oximetry oxygen saturation results and hematocrit was calculated by multiplying the hemoglobin times three.

Statistical analysis

All statistical analyses were performed using Stata software (Version 13.1, College Station, TX). The percent distribution of clinical variables among patients who survived and those who died were compared using the Fisher exact test. A multivariate logistic regression was done on treatments administered and severity of illness to determine which treatments were associated with survival. Mycophenolate mofetil was not included in this logistic regression analysis because 100 % of patients receiving mycophenolate mofetil survived. The association between severity of illness and treatments administered was assessed by performing a linear regression of treatments administered onto the modified APACHE 2 score.

Results

Demographic and exposure characteristics

There were a total of 51 cases, thirty patients (58.8 %) of whom were Saudi nationals, and 21 (41.2 %) were foreign nationals. The median age was 54 years old (IQR 36.5–58). Most were male (n = 40, 78.4 %). Twenty-one patients (41.2 %) had exposure to a known patient with MERS coronavirus and 12 (23.5 %) were healthcare workers. None of the patients had animal exposure. Two patients (3.9 %) were on pilgrimage to Mecca.

Overall, 71 % of patient had at least one co-morbid condition. Seventeen patients had diabetes (33.3 %), 25 had hypertension (49 %), 14 (27.5 %) had end stage renal disease, eight (15.7 %) had coronary artery disease and six (11.8 %) patients were immunosuppressed, two of whom were pregnant.

Clinical and laboratory findings

Forty-nine patients (96 %) had documented fever, 41 (80.4 %) had cough, and 46 (90 %) reported shortness of breath. Thirteen patients (25.5 %) had diarrhea, 12 (23.5 %) had vomiting and 5 (9.8 %) complained of sore throat. The clinical findings on presentation included eight patients (15.7 %) with hypotension, 39 (76.9 %) with tachypnea and 17 patients (33 %) with hypoxia. As previously reported, laboratory findings were non-specific. Fourteen patients (27.5 %) were anemic, 15 (29.4 %) were thrombocytopenic, and 28 (54.9 %) were leukopenic. Many patients had liver function abnormalities. Twenty-three (45.1 %) had elevated ALT and 35 (68.6 %) had an elevated AST. Thirty-two patients (62.8 %) had an elevated LDH, 24 patients (47.1 %) had an elevated CK and 21 patients (41.2 %) had an elevated creatinine.

Treatments administered

Patients received a variety of novel treatments including immunosuppressants and antivirals. Forty-two (82.4 %) patients received broad-spectrum antibiotics and five (9.8 %) received hydrocortisone. Thirty one patients received antiviral treatment. Twenty-three patients (45.1 %) were treated with interferon beta, eight (15.7 %) were treated with interferon alpha. A variety of anti-viral combinations were used. Eight patients (15.7 %) received mycophenolate mofetil, seven of these patients received it in combination with interferon beta. Nineteen (37.3 %) patients required intensive care unit (ICU) care, and 10 patients received extracorporeal membrane oxygenation (ECMO). All patients treated in the ICU and all patients receiving ECMO died.

Univariable association of demographic, clinical features and treatment with death

In this recent cohort, when comparing survivors to non-survivors, survival was associated with male gender, vomiting on admission, elevated respiratory rate, abnormal lung exam on physical exam, working as a healthcare worker, history of hypertension, elevated ALT, clearance of MERS CoV on repeat PCR testing, and receiving mycophenolate mofetil or beta interferon (Table 1). In contrast, markers of severe disease like hypotension, hypoxemia, chest radiographic abnormalities, leukocytosis, elevated creatinine, thrombocytopenia, anemia, renal failure were associated with death.
Table 1

Predictors for poor outcome among 51 MERS CoV cases in KSA 2014

 

Total

Survival

Death

P value

Demographics and Epidemiology

    

Age < = 30

7 (13.7 %)

6 (85.7 %)

1 (14.29 %)

0.187

Age 31-60

32 (62.8 %)

22 (64.7 %)

12 (35.3 %)

 

Age >60

10 (19.6 %)

4 (40 %)

6 (60 %)

 

Gender - male

40 (78.4 %)

22(55 %)

18(45 %)

0.037

Known MERS exposure

21 (41.2 %)

12 (57.1 %)

9 (42.9 %)

0.563

Healthcare worker

12 (23.5 %)

11 (91.7 %)

1 (8.3 %)

0.020

Umrah patient

2 (3.9 %)

2 (100 %)

0 (0 %)

0.523

Co-morbid conditions

    

Diabetes

17 (33.3 %)

9 (52.9 %)

8 (47.1 %)

0.365

Hypertension

25 (49 %)

10 (40 %)

15 (60 %)

0.001

End stage renal disease

14 (27.5 %)

6 (42.9 %)

8 (57.1 %)

0.106

Coronary artery disease

8 (15.7 %)

3 (37.5 %)

5 (62.5 %)

0.131

Immunosuppression

6 (11.8 %)

5 (83.3 %)

1 (16.7 %)

0.392

Signs and Symptoms

    

Runny nose

6 (11.8 %)

5 (83.3 %)

1 (16.67 %)

0.392

Cough

41(80.4 %)

26 (63.4 %)

15(36.6 %)

1.000

Diarrhea

13 (25.5 %)

11 (84.6 %)

2 (15.4 %)

0.096

Vomiting

12 (23.5 %)

11 (91.7 %)

1 (8.3 %)

0.020

Sore throat

5 (9.8 %)

3 (60 %)

2 (40 %)

1.000

Abnormal lung exam

20 (39.2 %)

17 (85 %)

3 (15 %)

0.016

Subjective fever

49 (96.1 %)

30 (61.2 %)

19 (38.8 %)

0.523

Temperature >38 Celsius

25 (49 %)

13 (52 %)

12 (48 %)

0.153

Respiratory rate >16

39 (76.5 %)

21 (53.9 %)

18 (46.2 %)

0.020

Blood pressure < 90/60 mm Hg

8 (15.7 %)

0 (0 %)

8 (100 %)

0.000

Oxygen saturation < 90 %

17 (33.3 %)

4 (23.5 %)

13 (76.5 %)

0.000

Laboratory findings

    

Hemoglobin < 10 g/dL

14 (27.5 %)

4 (28.6 %)

10 (71.4 %)

0.003

White Blood cell count < 5,000 cells/mm3

28 (54.9 %)

21 (75 %)

7 (25 %)

0.080

White Blood cell count > 10,000 cells/mm3

9 (17.6 %)

2 (22.2 %)

7 (77.8 %)

0.009

Platelets < 150,000/mm3

15 (29.4 %)

9 (60 %)

6 (40 %)

1.000

ALT > 50 U/L

23 (45.1 %)

14 (61 %)

9 (39.1 %)

1.000

AST > 40 U/L

35 (68.6 %)

18 (51.4 %)

17 (48.6 %)

0.015

LDH > 300 U/L

32 (62.7 %)

18 (56.3 %)

14 (43.8 %)

0.247

Creatinine > 1.5 mg/dL

21 (41.2 %)

8 (38.1 %)

13 (61.9 %)

0.003

CK > 200 U/L

24 (47.1 %)

13 (54.2 %)

11 (45.8 %)

0.261

Potassium > 4.5 mmol/L

17 (33.3 %)

8 (47.1 %)

9 (52.9 %)

0.131

Negative repeat PCR swab

31 (60.8 %)

30 (96.8 %)

1 (3.23 %)

0.000

Radiology

    

CXR – Right upper lobe infiltrate

17 (33.3 %)

5 (29.4 %)

12 (70.6 %)

0.001

CXR – Right lower lobe infiltrate

32 (62.7 %)

13 (40.6 %)

19 (59.4 %)

0.000

CXR – Left upper lobe infiltrate

19 (37.3 %)

7 (36.8 %)

12 (63.2 %)

0.006

CXR – Left lower lobe infiltrate

31 (60.8 %)

13 (41.9 %)

18 (58.1 %)

0.000

Treatments administered

    

Interferon beta

23 (45.1 %)

18 (78.3 %)

5 (21.7 %)

0.047

Interferon alpha

8 (15.7 %)

6 (75 %)

2 (25 %)

0.694

Any interferon

31 (60.8 %)

24 (77.4 %)

7 (22.6 %)

0.009

Ribavirin

19 (37.5 %)

13 (68.4 %)

6 (13.6 %)

0.564

Antibiotics

42 (82.4 %)

26 (61.9 %)

16 (38.1 %)

1.000

Hydrocortisone

5 (9.8 %)

2 (40 %)

3 (60 %)

0.348

Mycophenolate mofetil

8 (15.7 %)

8 (100 %)

0 (0 %)

0.019

ICU stay during admission

19 (37.3 %)

0 (0 %)

19 (100 %)

0.000

Extracorporeal Membrane Oxygenation

10 (19.6 %)

0 (0 %)

10 (100 %)

0.000

Treatments given

Treatments given were based as indicated based on the clinical assessment of the infectious disease consult team. Thirty-one patients received antivirals, ribavirin or alpha or beta interferon, and 13 patients received immunosuppressive medication. Most patients received a combination of alpha interferon and ribavirin (5, 9.8 %), beta interferon and ribavirin (10, 19.5 %) or beta interferon alone (11, 21.6 %). Two patients received alpha interferon alone (3.9 %). Eight patients received mycophenolate mofetil (15.7 %) and seven of them received this in combination with beta-interferon. Five patients received hydrocortisone; two in combination with beta interferon and ribavirin and 3 in combination with alpha interferon and ribavirin. All eight patients given mycophenolate mofetil survived therefore mycophenolate mofetil could not be evaluated in this model.

Impact of treatments

While the results of the univariable analysis demonstrated improved survival in patients treated with beta-interferon and mycophenolate mofetil, the multivariable analysis which included a marker of severity of illness, demonstrated a strong association between severity of illness and reduced survival, and no association between treatment with beta interferon and survival. Mycophenolate mofetil was not evaluable in this model (Table 2). In analyzing the relationship between severity of illness and treatments administered, beta interferon and mycophenolate mofetil were given to less severely ill patients (Table 3)
Table 2

Multivariable analysis of treatments and their impact on mortality

 

Odds ratio

Confidence interval

P value

Beta interferon

0.68

0.04–10.28

0.778

Alpha interferon

0.47

0.02–10.38

0.630

Hydrocortisone

2.92

0.13–63.62

0.495

Ribavirin

0.66

0.04–12.36

0.779

Modified APACHE 2 score

1.60

1.18–2.17

0.002

Table 3

Univariable analysis of the impact of severity of illness on treatments administered

 

Risk association

Confidence interval

P value

Beta interferon

– 4.62

−8.40, −0.84

0.018

Alpha interferon

– 1.24

−6.71, 4.24

0.652

Ribavirin

0.78

−3.34,4.90

0.704

Viral treatment

– 5.98

−9.73, −2.23

0.002

Mycophenolate mofetil

– 7.91

−12.90, −2.91

0.003

Hydrocortisone

3.03

−3.62,9.68

0.364

Discussion

MERS-CoV is an emerging disease for which the initial epidemiology has been described, but in-depth clinical studies and the role of therapy in incompletely understood. While the clinical features for MERS-CoV have been described in several large case series [614], there is a paucity of literature on therapy. Our results from a relatively large number of patients demonstrate similar clinical features and mortality to previous studies [614]. In our cohort, treatment with beta interferon and mycophenolate mofetil may be predictive of survival, but the greatest predictor of survival is the severity of illness on presentation.

Improved diagnostics have demonstrated an expanded spectrum of disease that includes less severe cases than previously reported. We now understand that MERS-CoV causes an acute respiratory disease syndrome and one third of patients present with gastrointestinal symptoms [14]. Fever has been seen in 62–87 % of patients, cough in 55–87 %, and gastrointestinal symptoms in 26–35 %. Seventy-six to 96 % percent of patients have had comorbid illnesses, most commonly chronic renal failure, diabetes and heart disease [715]. This may be partially related to the epidemiology of increased disease transmission in healthcare settings rather than a true host risk factor. Laboratory findings have been non-specific and consistent with other viral infections. Thrombocytopenia (75 %) and lymphopenia (58 %) have been commonly described in these patients [7, 913, 15]. Forty three percent had acute kidney injury [7, 1113, 17] and 76–100 % had CXR abnormalities with bibasilar infiltrates as the most common finding [813, 15, 18]. The outcomes in these more severely ill patients remain poor. Between 50–90 % required ICU care [10, 11, 13, 15] and 67–100 % in the ICU setting required invasive ventilation for a median of 7–16 days [8, 10, 12]. In addition to mechanical ventilation, several patients have received extracorpeal membrane oxygenation (ECMO) to support ventilation. From non-randomized data from the World Health Organization, five out of six patients receiving ECMO died [9]. Fifty-eight to 75 % required renal replacement therapy [11, 12, 17] and 30–60 % of hospitalized patients died [715]. The severity of illness can be partially explained by the widespread lung disease caused by MERS-CoV and it appears that mortality in those patients requiring intensive care is extremely high. Although no autopsy data is available, in explanted lung, infection with MERS-CoV causes widespread infection and alveolar disease [19, 20].

The clinical features in our cohort similarly also show a high proportion of patients with fever (96 %) and cough (80.4 %) shortness of breath (90 %), and almost one third of patients (29.4 %) with gastrointestinal symptoms. Our cohort consisted of ill patients with hypotension (15.7 %), tachypnea (76.9 %) and hypoxia (33 %). Thirty seven percent required ICU care and 10 patients received ECMO. Similar to previous results, all of the patients who received ECMO died [9].

There is no known effective treatment for MERS CoV. Many compounds have been screened in vitro for possible activity against this coronavirus [2124], however, the in vivo efficacy has not been subjected to clinical investigation.

In vitro data suggests that MERS-CoV inhibits host interferon production through various molecular pathways [2530] mycophenic acid, the active agent of prodrug mycophenolate mofetil, and cyclosporine strongly inhibit MERS coronavirus in human and monkey cell lines even more so than they inhibit SARS coronavirus [24, 3133]. Interferon alpha and interferon beta reduce MERS coronavirus replication in explanted lung tissue [19]. In vivo, comparing host response in two patients with MERS coronavirus and differing outcomes, the patient who was able to clear MERS CoV infection was able to mount an interferon response and the patient who died had low levels of interferon alpha suggesting a therapeutic role for interferon [34]. The combination of interferon alpha and ribavirin has been used successfully in rhesus monkeys infected with MERS coronavirus [35], and in a few small case series [3638]. Beta-interferon seems to be an even more potent inhibitor of MERS coronavirus in vitro [19] [24, 3133]. One small study with exceptionally high mortality rates using interferon beta for treatment found no difference in mortality between interferon beta use and interferon alpha use [39]. Our data, albeit from a retrospective cohort support the findings that interferon beta is associated with a decrease in mortality.

There are limited data on the efficacy of treatment regiments for this virulent disease. We present data from a retrospective cohort of ill patients with Mers-CoV and the results of the evaluation of the clinical efficacy of beta interferon beta, alpha interferon, ribavirin and mycophenolate mofetil in addition to routine supportive care. Forty five percent of patents (23 patients) received interferon beta and in this cohort, sixteen percent of patients received interferon alpha (8 patients) and 37 % of patients (9 patients) received ribavirin, either in conjunction with interferon alpha or interferon beta, and 8 patient received mycophenolate mofetil. Patients receiving beta interferon and mofetil had improved survival, however this was confounded by the severity of illness on presentation for beta interferon. All of the patients who received mycophenolate mofetil survived however because of the small number, we could not analyze the independent efficacy of mycophenolate mofetil.

While this is a relatively large series of MERS-CoV cases, the primary limitation of our study is that it is a retrospective review of cases and not a randomized trial and thus subject to confounding as seen in our cohort. We used a modified APACHE 2 score without all of the clinical variables, which may have underestimated the association of severity of illness with reduced survival. Importantly, the mortality in patients receiving additional therapies that modulate the immune response was low. All of the eight patients who received mycophenolate mofetil in our study survived. Hence, it may be reasonable to further study this agent in controlled trials.

Conclusions

This observational study investigates novel treatment options like beta interferon and mycophenolate mofetil for MERS-CoV in humans which have in vitro activity. Our cohort demonstrated severity of illness is an important effect modifier and needs to be considered in evaluating novel agents. To better assess the efficacy of these therapies, international prospective randomized trials with adequate numbers of patients are needed to further evaluate the impact of these treatments in addition to routine supportive care when compared to other treatment options.

Ethics approval

This study was reviewed and approved by Johns Hopkins University Institutional Review Board and the Directorate of Health Affairs.

Availability of data and materials

Data supporting the findings are in the manuscript, additional data available upon request.

Abbreviations

AIDS: 

acquired immune deficiency syndrome

ALT: 

alanine transaminase

APACHE 2: 

acute physiologic and chronic health evaluation

AST: 

aspartate aminotransferase

CXR: 

chest x ray

ECMO: 

extracorporeal membrane oxygenation

ICU: 

intensive care unit

LDH: 

lactate dehydrogenase

MERS Co-V: 

Middle Eastern Respiratory Syndrome coronavirus

PCR: 

polymerase chain reaction

Declarations

Acknowledgements

There are no acknowledgements.

Funding

There was no external funds provided for this project.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
King Fahd General Hospital
(2)
Department of Medicine, Division of General Internal Medicine, The Johns Hopkins University, School of Medicine
(3)
Department of Internal Medicine, Division of Infectious Diseases, The Johns Hopkins University, School of Medicine

References

  1. Peiris JS, Yuen KY, Osterhaus AD, Stöhr K. The severe acute respiratory syndrome. N Engl J Med. 2003;349(25):2431–41.View ArticlePubMedGoogle Scholar
  2. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814–20.View ArticlePubMedGoogle Scholar
  3. Wise J. Patient with new strain of coronavirus is treated in intensive care at London hospital. BMJ. 2012;345:e6455.View ArticlePubMedGoogle Scholar
  4. Pollack MP, Pringle C, Madoff LC, Memish ZA. Latest outbreak news from ProMED-mail: novel coronavirus -- Middle East. Int J Infect Dis. 2013;17(2):e143–4.View ArticlePubMedGoogle Scholar
  5. de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, Fouchier RA, Galiano M, Gorbalenya AE, Memish ZA, Perlman S, Poon LL, Snijder EJ, Stephens GM, Woo PC, Zaki AM, Zambon M, Ziebuhr J. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol. 2013;87(14):7790–2.View ArticlePubMedPubMed CentralGoogle Scholar
  6. WHO summary http://www.who.int/csr/don/4-january-2016-mers-saudi-arabia/en/accessed 12 Dec 2015.
  7. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM. Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med. 2013;368(26):2487–94.View ArticlePubMedGoogle Scholar
  8. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, Alabdullatif ZN, Assad M, Almulhim A, Makhdoom H, Madani H, Alhakeem R, Al-Tawfiq JA, Cotten M, Watson SJ, Kellam P, Zumla AI, Memish ZA; KSA MERS-CoV Investigation Team. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med. 2013;369(5):407–16.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Who Mers-Cov Research Group. State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans. PLoS Curr. 2013;12:5.Google Scholar
  10. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, Flemban H, Al-Nassir WN, Balkhy HH, Al-Hakeem RF, Makhdoom HQ, Zumla AI, Memish ZA. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13(9):752–61.View ArticlePubMedGoogle Scholar
  11. Saad M, Omrani AS, Baig K, Bahloul A, Elzein F, Matin MA, Selim MA, Mutairi MA, Nakhli DA, Aidaroos AY, Sherbeeni NA, Al-Khashan HI, Memish ZA, Albarrak AM. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis. 2014;29:301–6.View ArticlePubMedGoogle Scholar
  12. Arabi YM, Arifi AA, Balkhy HH, Najm H, Aldawood AS, Ghabashi A, Hawa H, Alothman A, Khaldi A, Al Raiy B. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med. 2014;160(6):389–97.View ArticlePubMedGoogle Scholar
  13. Al-Abdallat MM, Payne DC, Alqasrawi S, Rha B, Tohme RA, Abedi GR, Al Nsour M, Iblan I, Jarour N, Farag NH, Haddadin A, Al-Sanouri T, Tamin A, Harcourt JL, Kuhar DT, Swerdlow DL, Erdman DD, Pallansch MA, Haynes LM, Gerber SI; Jordan MERS-CoV Investigation Team. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin Infect Dis. 2014;59(9):1225–33.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Memish ZA, Zumla AI, Assiri A. Middle East respiratory syndrome coronavirus infections in health care workers. N Engl J Med. 2013;369(9):884–6.View ArticlePubMedGoogle Scholar
  15. Al-Tawfiq JA, Hinedi K, Ghandour J, Khairalla H, Musleh S, Ujayli A, Memish ZA. Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients. Clin Infect Dis. 2014;59(2):160–5.View ArticlePubMedGoogle Scholar
  16. Knaus WA et al. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818–29.View ArticlePubMedGoogle Scholar
  17. Eckerle I, Müller MA, Kallies S, Gotthardt DN, Drosten C. In-vitro renal epithelial cell infection reveals a viral kidney tropism as a potential mechanism for acute renal failure during Middle East Respiratory Syndrome (MERS) Coronavirus infection. J Virol. 2013;10:359. doi:10.1186/1743-422X-10-359.View ArticleGoogle Scholar
  18. Ajlan AM, Ahyad RA, Jamjoom LG, Alharthy A, Madani TA. Middle East respiratory syndrome coronavirus (MERS-CoV) infection: chest CT findings. AJR Am J Roentgenol. 2014;203(4):782–7.View ArticlePubMedGoogle Scholar
  19. Chan RW, Chan MC, Agnihothram S, Chan LL, Kuok DI, Fong JH, Guan Y, Poon LL, Baric RS, Nicholls JM, Peiris JS. Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures. J Virol. 2013;87(12):6604–14.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Hocke AC, Becher A, Knepper J, Peter A, Holland G, Tönnies M, Bauer TT, Schneider P, Neudecker J, Muth D, Wendtner CM, Rückert JC, Drosten C, Gruber AD, Laue M, Suttorp N, Hippenstiel S, Wolff T. Emerging human middle East respiratory syndrome coronavirus causes widespread infection and alveolar damage in human lungs. Am J Respir Crit Care Med. 2013;188(7):882–6.View ArticlePubMedGoogle Scholar
  21. Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, Johnson RF, Olinger GG Jr, Jahrling PB, Laidlaw M, Johansen LM, Lear-Rooney CM, Glass PJ, Hensley LE, Frieman MB. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014;58(8):4885–93.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Adedeji AO, Singh K, Kassim A, Coleman CM, Elliott R, Weiss SR, Frieman MB, Sarafianos SG. Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses. Antimicrob Agents Chemother. 2014;58(8):4894–8.View ArticlePubMedPubMed CentralGoogle Scholar
  23. de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, van den Hoogen BG, Neyts J, Snijder EJ. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58(8):4875–84.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, Li PT, Dai J, Mok FK, Chen H, Hayden FG, Yuen KY. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect. 2013;67(6):606–16.View ArticlePubMedGoogle Scholar
  25. Gralinski LE, Baric RS. Molecular pathology of emerging coronavirus infections. J Pathol. 2015;235(2):185–95.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Niemeyer D, Zillinger T, Muth D, Zielecki F, Horvath G, Suliman T, Barchet W, Weber F, Drosten C, Müller MA. Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist. J Virol. 2013;87(22):12489–95.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Menachery VD, Eisfeld AJ, Schäfer A, Josset L, Sims AC, Proll S, Fan S, Li C, Neumann G, Tilton SC, Chang J, Gralinski LE, Long C, Green R, Williams CM, Weiss J, Matzke MM, Webb-Robertson BJ, Schepmoes AA, Shukla AK, Metz TO, Smith RD, Waters KM, Katze MG, Kawaoka Y, Baric RS. Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses. MBio. 2014;5(3):e01174–14.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Yang X, Chen X, Bian G, Tu J, Xing Y, Wang Y, Chen Z. Proteolytic processing, deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like protease. J Gen Virol. 2014;95(Pt 3):614–26.View ArticlePubMedGoogle Scholar
  29. Yang Y, Zhang L, Geng H, Deng Y, Huang B, Guo Y, Zhao Z, Tan W. The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell. 2013;4(12):951–61.View ArticlePubMedGoogle Scholar
  30. Matthews KL, Coleman CM, van der Meer Y, Snijder EJ, Frieman MB. The ORF4b-encoded accessory proteins of Middle East respiratory syndrome coronavirus and two related bat coronaviruses localize to the nucleus and inhibit innate immune signalling. J Gen Virol. 2014;95(Pt 4):874–82.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Kindler E, Jónsdóttir HR, Muth D, Hamming OJ, Hartmann R, Rodriguez R, Geffers R, Fouchier RA, Drosten C, Müller MA, Dijkman R, Thiel V. Efficient replication of the novel human betacoronavirus EMC on primary human epithelium highlights its zoonotic potential. MBio. 2013;4(1):e00611–2.View ArticlePubMedPubMed CentralGoogle Scholar
  32. de Wilde AH, Raj VS, Oudshoorn D, Bestebroer TM, van Nieuwkoop S, Limpens RW, Posthuma CC, van der Meer Y, Bárcena M, Haagmans BL, Snijder EJ, van den Hoogen BG. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment. J Gen Virol. 2013;94(Pt 8):1749–60.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Hart BJ, Dyall J, Postnikova E, Zhou H, Kindrachuk J, Johnson RF, Olinger GG Jr, Frieman MB, Holbrook MR, Jahrling PB, Hensley L. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol. 2014;95(Pt 3):571–7.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Faure E, Poissy J, Goffard A, Fournier C, Kipnis E, Titecat M, Bortolotti P, Martinez L, Dubucquoi S, Dessein R, Gosset P, Mathieu D, Guery B. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? PLoS One. 2014;9(2):e88716.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Falzarano D, de Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, Brining D, Bushmaker T, Martellaro C, Baseler L, Benecke AG, Katze MG, Munster VJ, Feldmann H. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013;19(10):1313–7.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaidaroos AY, Almakhlafi GA, Albarrak MM, Memish ZA, Albarrak AM. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14(11):1090–5.View ArticlePubMedGoogle Scholar
  37. Khalid M, Al Rabiah F, Khan B, Al Mobeireek A, Butt TS, Al ME. Ribavirin and interferon (IFN)-alpha-2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus (MERS-CoV): a preliminary report of two cases. Antivir Ther. 2015;20(1):87–91.View ArticlePubMedGoogle Scholar
  38. Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis. 2014;20:42–6.View ArticlePubMedGoogle Scholar
  39. Shalhoub S, Farahat F, Al-Jiffri A, Simhairi R, Shamma O, Siddiqi N, Mushtaq A. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother. 2015;70(7):2129–32.Google Scholar

Copyright

© Al Ghamdi et al. 2016

Advertisement